94 1.3.1.1. Rationale for Galinpepimut-S and Pembrolizumab Combination Therapy ....... 95 1.3.1.2. Rationale for Selection of Indications ................................................................ 98 1.3.1.2.1. Metastatic Colorectal Cancer (Third/Fourth line) .......................................... 98 1.3.1.2.2. Ovarian Cancer (Second/Third line) ............................................................ 100 SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 10 1.3.1.2.3. Small Cell Lung Cancer (Second Line) ....................................................... 101 1.3.1.2.4. Breast Cancer (Triple Negative; Second Line) ............................................ 102 1.3.1.2.5. Acute Myelogenous Leukemia (AML) ........................................................ 103 2 Study Objectives ............................................................................................................